Preparation and evaluation of controlled release tablets of carvedilol

Main Article Content

M L Varahala Setti
J Vijaya Ratna


The objective of the present investigation is to design and evaluate controlled release tablets of carvedilol, employing synthetic polymers like polyethylene oxides, of different molecular weights as release retarding materials and to select
the optimized formulation based on the pharmacokinetics of carvedilol. Matrix tablets each containing 80 mg of carvedilol were formulated employing PEO N60 K, PEO 301, and PEO 303 as release-retarding polymers and β Cyclodextrin and
HP β cyclodextrin as release modulators from the matrix. Carvedilol release from the formulated tablets was very slow. Hence the release was modulated with the use of cyclodextrins. The dissolution from the matrix tablets was spread over
more than 24 hours and depended on the type of polymer, its concentration and the type of cyclodextrin used. All the matrix tablets prepared using polyethylene oxides showed very good controlled release over more than 24 hours.The matrix tablets prepared using HP β cyclodextrin showed a higher dissolution rate and gave a dissolution profile that was comparable to the theoretical sustained release needed for once-a-day administration of carvedilol. The drug release mechanism from the matrix tablets was found to be quasi Fickian mechanism.


Download data is not yet available.

Article Details

How to Cite
Setti, M. L. V., & Ratna, J. V. (2014). Preparation and evaluation of controlled release tablets of carvedilol. Asian Journal of Pharmaceutics (AJP), 3(3).


Ruffolo RR Jr, Feuerstein GZ. Pharmacology of carvedilol: Rational for

use in hypertension, coronary artery disease, and congestive heart

failure. Cardiovasc Drugs Ther 1997:11:247-56.

Ruffolo RR Jr, Gellai M, Hieble JP, Willette RN, Nichols AJ. The

pharmacology of carvedilol Eur J Clin Pharmacol 1990;38:S82-8.

McTavish D, Campoli-Richards D, Sorkin EM. Carvedilol: A review of

its pharmacodynamic and pharmacokinetic properties and therapeutic

efficacy. Drugs 1993;45:232-58.

Apicella A, Cappello B, Del Nobile MA, La Rotonda MI, Mensitieri G,

Nicolais L. Poly (ethylene oxide) (PEO) and different molecular

weight PEO blends monolithic devices for drug release. Biomaterials


Zhang F, McGinity JW. Properties of sustained-release tablets prepared

by hot-melt extrusion. Pharm Dev Technol 1999;4:241-50.

Razaghi AM, Schwartz JB. Investigation of Cyclobenzaprine HCl Release

from Oral Osmotic Delivery Systems Containing a Water-Swellable

Polymer. Drug Dev Ind Pharm 2002;28:631-9.

Jamzad S, Fassihi R. Development of a controlled release low dose

class II drug-Glipizide. Int J Pharm 2006;312:24-32.

Wagner JG, Nelson E. Percent absorbed time plots derived from blood

level and/or urinary excretion data. J Pharm Sci 1963;52:610-1.

Rudnic, EM, Kottke MK. Tablet Dosage Forms. In: Modern Pharmaceutics.

Banker GS, Rhodes CT, editors. 3rd ed. New York: Marcel Dekker, Inc;

p. 333-94.

Higuchi T. Mechanism of sustained action medication: Theoretical

analysis of rate of release of solid drugs dispersed in solid matrices Pharm Sci 1963;52:1145-9.

Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanism

of solute release from porous hydrophilic polymers. Int J Pharma


Basak SC, Jayakumar Reddy BM, Lucas Mani KP. Formulation and release

behaviour of sustained release ambroxol hydrochloride HPMC matrix

tablet. Indian J Pharm Sci 2006;68:594-8.